JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Among these, H19 was upregulated after JAK2 inhibition (Supplementary Figure 4B), opposite to BCR-ABL1 inhibition in CML cells (Supplementary Figure 1A).